Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned

dc.contributor.authorShugg, Tyler
dc.contributor.authorTillman, Emma M.
dc.contributor.authorBreman, Amy M.
dc.contributor.authorHodge, Jennelle C.
dc.contributor.authorMcDonald, Christine A.
dc.contributor.authorLy, Reynold C.
dc.contributor.authorRowe, Elizabeth J.
dc.contributor.authorOsei, Wilberforce
dc.contributor.authorSmith, Tayler B.
dc.contributor.authorSchwartz, Peter H.
dc.contributor.authorCallaghan, John T.
dc.contributor.authorPratt, Victoria M.
dc.contributor.authorLynch, Sheryl
dc.contributor.authorEadon, Michael T.
dc.contributor.authorSkaar, Todd C.
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2024-11-19T10:52:48Z
dc.date.available2024-11-19T10:52:48Z
dc.date.issued2024
dc.description.abstractIn 2019, Indiana University launched the Precision Health Initiative to enhance the institutional adoption of precision medicine, including pharmacogenetics (PGx) implementation, at university-affiliated practice sites across Indiana. The overarching goal of this PGx implementation program was to facilitate the sustainable adoption of genotype-guided prescribing into routine clinical care. To accomplish this goal, we pursued the following specific objectives: (i) to integrate PGx testing into existing healthcare system processes; (ii) to implement drug-gene pairs with high-level evidence and educate providers and pharmacists on established clinical management recommendations; (iii) to engage key stakeholders, including patients to optimize the return of results for PGx testing; (iv) to reduce health disparities through the targeted inclusion of underrepresented populations; (v) and to track third-party reimbursement. This tutorial details our multifaceted PGx implementation program, including descriptions of our interventions, the critical challenges faced, and the major program successes. By describing our experience, we aim to assist other clinical teams in achieving sustainable PGx implementation in their health systems.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationShugg T, Tillman EM, Breman AM, et al. Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned. Clin Pharmacol Ther. 2024;116(4):914-931. doi:10.1002/cpt.3402
dc.identifier.urihttps://hdl.handle.net/1805/44614
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/cpt.3402
dc.relation.journalClinical Pharmacology and Therapeutics
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectAcademic medical centers
dc.subjectPharmacogenetics
dc.subjectPharmacogenomic testing
dc.subjectPrecision medicine
dc.titleDevelopment of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Shugg2024Development-AAM.pdf
Size:
1.38 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: